Atria Wealth Solutions Inc. Sells 193 Shares of Agilent Technologies, Inc. (NYSE:A)

Atria Wealth Solutions Inc. lowered its position in Agilent Technologies, Inc. (NYSE:A) by 9.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,773 shares of the medical research company’s stock after selling 193 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Agilent Technologies were worth $246,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Carmel Capital Partners LLC raised its position in Agilent Technologies by 1.2% in the fourth quarter. Carmel Capital Partners LLC now owns 6,709 shares of the medical research company’s stock worth $933,000 after purchasing an additional 78 shares in the last quarter. Kepos Capital LP raised its holdings in shares of Agilent Technologies by 3.5% in the 3rd quarter. Kepos Capital LP now owns 2,775 shares of the medical research company’s stock worth $310,000 after buying an additional 93 shares in the last quarter. Rosenberg Matthew Hamilton lifted its position in shares of Agilent Technologies by 51.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after buying an additional 96 shares during the period. Balentine LLC boosted its stake in Agilent Technologies by 3.4% in the 3rd quarter. Balentine LLC now owns 3,180 shares of the medical research company’s stock valued at $356,000 after buying an additional 104 shares in the last quarter. Finally, Sonen Capital LLC grew its position in Agilent Technologies by 3.6% in the third quarter. Sonen Capital LLC now owns 3,050 shares of the medical research company’s stock valued at $341,000 after acquiring an additional 105 shares during the period.

Analyst Ratings Changes

A has been the subject of a number of analyst reports. Citigroup lifted their price objective on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Evercore ISI upped their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Oppenheimer lifted their target price on shares of Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. UBS Group increased their price target on Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Finally, Stifel Nicolaus upgraded Agilent Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the company from $145.00 to $163.00 in a research report on Friday, April 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and a consensus price target of $141.29.

Insider Activity

In other news, SVP Philip Binns sold 2,827 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total transaction of $417,095.58. Following the completion of the transaction, the senior vice president now directly owns 9,997 shares in the company, valued at approximately $1,474,957.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares in the company, valued at approximately $38,086,350. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Philip Binns sold 2,827 shares of Agilent Technologies stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the transaction, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The disclosure for this sale can be found here. Insiders have sold a total of 61,610 shares of company stock valued at $9,220,333 in the last 90 days.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $145.11 on Friday. The business’s 50-day simple moving average is $142.54 and its 200 day simple moving average is $132.31. The company has a quick ratio of 2.04, a current ratio of 2.68 and a debt-to-equity ratio of 0.41. The stock has a market cap of $42.52 billion, a price-to-earnings ratio of 34.55, a P/E/G ratio of 4.22 and a beta of 1.13. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $151.58.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.07. The company had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The company’s revenue for the quarter was down 5.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.37 EPS. As a group, research analysts anticipate that Agilent Technologies, Inc. will post 5.5 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd were given a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.65%. The ex-dividend date was Monday, April 1st. Agilent Technologies’s payout ratio is 22.38%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.